NCT07400588CompletedPhase 2
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Placebo-controlled, Study of the Safety and Tolerability of Aleniglipron in Adult Participants With Type 2 Diabetes Mellitus Living With Obesity or Overweight
Source: ClinicalTrials.gov · Last updated 21 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to assess the safety and tolerability of aleniglipron at doses up to 180 mg once daily (QD) in participants with T2DM who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2).
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 58 (actual)
- First submitted
- 28 Oct 2025
- Start date
- 1 Dec 2025
- Primary completion date
- 18 Sept 2026
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT07400588
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 58
- From 1 Dec 2025 to the primary completion date, 18 Sept 2026
- 14 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema. All participants must have a photo fundoscopy, optical coherence tomography, or slit lamp assessment prior to randomization and within the last 12 months to confirm the absence or stable status of diabetic retinopathy and/or macular edema.
- Self-reported change in body weight \>5 kg (11 pounds) within 3 months before screening
- Have prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty, if performed \>1 year prior to Screening)
- Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to Screening, including, but not limited to, mucosal ablation, gastric artery embolization, intragastric balloon, and duodenal-jejunal endoluminal liner
Lab values
- Present or planned use of any drug that could interfere with glucose levels
Who the study is looking for
- Signed Informed Consent
- A diagnosis of T2DM of ≥6 months,
- On stable treatment for T2DM for at least 90 days prior to Screening
- Hemoglobin A1c (HbA1c) ≥6.5% to ≤10% at Screening
- Have a BMI ≥27.0 kg/m2
Age in the registry: 18 years to 79 years · Sex: All · Does not accept healthy volunteers
Sites (14)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.